Elevated type-17 cytokines are present in axial spondyloarthritis stool.
India BroughKelsey ThompsonCiara LatoreFrank PenkavaChelsea ReganClaire PearsonHui ShiAnna RidleyDavide SimoneLilian LamSamuel BullersCaroline MoussaRachel Feeneynull nullMohammed H Al-MossawiFiona PowrieStephen P YoungCurtis HuttenhowerPaul BownessPublished in: Discovery immunology (2024)
Axial spondyloarthritis (axSpA) is characterized by type-17 immune-driven joint inflammation, and intestinal inflammation is present in around 70% of patients. In this study, we asked whether axSpA stool contained Th17-associated cytokines and whether this related to systemic Th17 activation. We measured stool cytokine and calprotectin levels by ELISA and found that patients with axSpA have increased stool IL-17A, IL-23, GM-CSF, and calprotectin. We further identified increased levels of circulating IL-17A+ and IL-17F+ T-helper cell lymphocytes in patients with axSpA compared to healthy donors. We finally assessed stool metabolites by unbiased nuclear magnetic resonance spectroscopy and found that multiple stool amino acids were negatively correlated with stool IL-23 concentrations. These data provide evidence of type-17 immunity in the intestinal lumen, and suggest its association with microbial metabolism in the intestine.
Keyphrases
- disease activity
- oxidative stress
- ankylosing spondylitis
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- stem cells
- systemic lupus erythematosus
- dendritic cells
- mesenchymal stem cells
- regulatory t cells
- ms ms
- cell therapy
- electronic health record
- big data
- patient reported outcomes
- data analysis
- cerebrospinal fluid